Format

Send to

Choose Destination
Intensive Care Med. 2006 Aug;32(8):1175-83. Epub 2006 Jun 2.

Persisting low monocyte human leukocyte antigen-DR expression predicts mortality in septic shock.

Author information

1
Immunology Laboratory, Hôpital Neurologique, Lyon, France. guillaume.monneret@chu-lyon.fr

Abstract

OBJECTIVE:

The immediate overwhelming release of inflammatory mediators in septic shock is rapidly followed by strong anti-inflammatory responses inducing a state of immunosuppression. The patients who survive the initial hyper-inflammatory step of septic shock but subsequently die may be those who do not recover from immunosuppression. We assessed whether a low monocyte human leukocyte antigen-DR (mHLA-DR) expression, proposed as a marker of immunosuppression, is an independent predictor of mortality in patients who survived the initial 48 h of septic shock.

DESIGN AND SETTING:

Prospective observational study performed in two adult intensive care units at a university hospital.

PATIENTS:

93 consecutive patients with septic shock.

MEASUREMENTS AND RESULTS:

At days 1-2, mHLA-DR values (determined by flow cytometry) were not significantly different between survivors and non-survivors. A sharp difference became highly significant at days 3-4 when survivors had increased their values, while non-survivors had not (43% vs. 18%, percentage of HLA-DR positive monocyte, p < 0.001). Multivariate logistic regression analysis revealed that low mHLA-DR (< 30%) at days 3-4 remained independently associated with mortality after adjustment for usual clinical confounders, adjusted odds ratio (CI): 6.48 (95% CI: 1.62-25.93).

CONCLUSION:

The present preliminary results show that mHLA-DR is an independent predictor of mortality in septic shock patients. Being a marker of immune failure, low mHLA-DR may provide a rationale for initiating therapy to reverse immunosuppression. After validation of the current results in multicenter studies, mHLA-DR may help to stratify patients when designing a mediator-directed therapy in a time-dependent manner.

PMID:
16741700
DOI:
10.1007/s00134-006-0204-8
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center